3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Recruiting
2
Completed
2
Terminated
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Sarcoma
1
Conditions
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Hemangiosarcoma
1
Interventions
pembrolizumab
550
Specimen Handling
462
Carboplatin
441
Magnetic Resonance Spectroscopy
429
Cyclophosphamide
412
Cisplatin
398
Radiotherapy
313
Gemcitabine
310
Bevacizumab
306
Paclitaxel
294
Biopsy
259
Drug Therapy
248
Capecitabine
241
Oxaliplatin
239
fludarabine
238
Nivolumab
224
venetoclax
219
Injections
213
Docetaxel
205
Fluorouracil
202
Dexamethasone
186
Radiosurgery
172
Rituximab
158
Pemetrexed
153
Standard of Care
145
durvalumab
143
Leucovorin
138
atezolizumab
137
toripalimab
134
tislelizumab
134
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Interventional
×
SGN-LIV1A
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled
NCT03424005
2026-03-16
Morpheus-panBC
Hoffmann-La Roche
Phase 1/2
Recruiting
792 enrolled